Testosterone and erectile dysfunction are closely linked in public discussion, but the clinical relationship is more specific than many men are led to believe. Testosterone supports libido, nitric oxide signaling, penile tissue health, mood, energy, and body composition. Erectile function, however, also depends on vascular integrity, nerve signaling, medication exposure, sleep, alcohol intake, metabolic health, and psychological state. Low testosterone can contribute to erectile dysfunction, but it is rarely the only variable.
Testosterone and Erectile Dysfunction: A Physiologic Overview
Erection is a neurovascular event. Sexual stimulation activates parasympathetic pathways that increase nitric oxide release in penile tissue. Nitric oxide increases cyclic guanosine monophosphate, or cGMP, which relaxes cavernosal smooth muscle and allows arterial inflow. The penis becomes rigid when inflow is adequate and venous outflow is restricted.
Testosterone influences this system at several levels. Androgen signaling appears to support nitric oxide synthase activity, smooth muscle structure, cavernosal tissue maintenance, and sexual desire. When testosterone is substantially low, some men experience reduced libido, fewer morning erections, lower arousal, fatigue, depressed mood, or reduced response to sexual stimulation. These symptoms can overlap with erectile dysfunction but are not identical to it.
This distinction matters clinically. A man with normal libido but unreliable firmness after alcohol, stress, or reduced sleep may have a vascular or medication-related problem rather than a primary androgen problem. Conversely, a man with reduced sexual desire, low morning erections, fatigue, and repeatedly low morning testosterone may need endocrine evaluation in addition to standard ED assessment.
When Low Testosterone Is Clinically Relevant
Guidelines generally emphasize that testosterone deficiency should not be diagnosed from symptoms alone. Total testosterone varies by time of day, illness, calorie intake, sleep, medications, and laboratory method. A single borderline value is not enough. Clinicians typically confirm low testosterone with repeat morning testing and interpret it alongside symptoms, sex hormone-binding globulin, free testosterone when appropriate, luteinizing hormone, prolactin, medication history, fertility goals, and comorbid disease.
The sexual symptoms most associated with androgen deficiency are low libido and reduced spontaneous erections. Erectile dysfunction can occur, but the association is strongest when testosterone is clearly low and symptoms are consistent. In men with normal testosterone, raising levels above physiologic need is not a reliable ED strategy and may introduce avoidable risks.
Recent reviews also emphasize mechanism. A 2024 review in Sexual Medicine Reviews summarized how androgen deficiency may impair erectile function through the nitric oxide-cGMP pathway, ion channel expression, oxidative stress, cavernosal cell death, and fibrosis. These mechanisms are biologically plausible, but they do not mean every ED presentation is hormone-driven. Erectile dysfunction is often multifactorial, especially in men with hypertension, dyslipidemia, diabetes, obesity, obstructive sleep apnea, depression, or heavy alcohol use.
What Testosterone Therapy Studies Show
Clinical trials suggest that testosterone replacement therapy may improve sexual symptoms in appropriately selected hypogonadal men, but the expected erectile-function effect is modest and context-dependent. The largest modern data are more nuanced than direct-to-consumer messaging often suggests.
In the TRAVERSE Sexual Function Study, men aged 45 to 80 with two testosterone concentrations below 300 ng/dL, hypogonadal symptoms, and cardiovascular disease or elevated cardiovascular risk were randomized to testosterone gel or placebo. The sexual-function substudy reported improvements in sexual activity and desire, with smaller effects on erectile function. This supports a clinically important point: testosterone may help men whose symptoms reflect androgen deficiency, but it is not simply an erection medication.
A 2024 Cochrane review evaluated randomized trials of testosterone for men with sexual dysfunction. In short-term studies up to 12 months, testosterone likely produced little to no clinically important difference in erectile function compared with placebo when measured by validated instruments. The review also noted uncertainty about longer-term effects. This does not contradict the role of testosterone in true hypogonadism. It shows that broad testosterone use for erectile complaints, especially without clear deficiency, is not strongly supported.
The practical implication is careful selection. Testosterone therapy may be relevant when repeated laboratory testing confirms deficiency and symptoms fit. For many men, first-line ED care still focuses on vascular risk, medication review, lifestyle factors, and phosphodiesterase type 5 inhibitors.
Why PDE5 Response Can Vary
PDE5 inhibitors such as tadalafil, sildenafil, and vardenafil act downstream of nitric oxide by slowing cGMP breakdown. They do not create sexual arousal and do not replace the need for intact nerve and vascular signaling. This explains why response varies among men and why the same medication may feel highly reliable for one person and inconsistent for another.
Low testosterone may contribute to PDE5 inhibitor nonresponse in some men, particularly when androgen deficiency reduces nitric oxide signaling or sexual desire. But nonresponse can also reflect inadequate dosing instructions, taking medication after a heavy meal when relevant, insufficient sexual stimulation, severe endothelial dysfunction, uncontrolled diabetes, pelvic surgery, nerve injury, relationship stress, antidepressants, heavy alcohol use, or unrealistic timing expectations.
Clinically, poor response should trigger reassessment rather than repeated dose escalation. A clinician may review the diagnosis, cardiovascular risk, blood pressure, glucose control, lipid status, sleep apnea symptoms, hormone testing, medication interactions, and whether the selected PDE5 inhibitor matches the patient's needs. Some men benefit from a longer-acting daily strategy; others prefer on-demand treatment. The appropriate choice depends on physiology, safety screening, and sexual pattern.
Testosterone, Metabolic Health, and Vascular Risk
Testosterone and erectile dysfunction also intersect through metabolic health. Obesity, insulin resistance, poor sleep, and chronic inflammation can reduce testosterone while simultaneously impairing endothelial function. In that setting, low testosterone may be both a contributor and a marker of broader cardiometabolic strain.
This is one reason ED should not be treated as an isolated bedroom problem. Penile arteries are small, and vascular impairment may become apparent there before symptoms appear in larger coronary or peripheral vessels. Men with new or worsening ED, especially in midlife, often deserve evaluation for blood pressure, lipids, glucose control, smoking exposure, sleep apnea, and cardiovascular risk.
Lifestyle interventions can improve several pathways at once. Resistance training and aerobic exercise may support endothelial function, insulin sensitivity, body composition, mood, and testosterone biology. Weight loss in men with obesity can improve testosterone levels and erectile function. Sleep regularity may improve hormonal rhythm and sexual performance. Reducing heavy alcohol intake may improve both erectile reliability and testosterone regulation. These interventions are not instant substitutes for medical treatment, but they address root physiology rather than only short-term symptom control.
Testing and Treatment Decisions
A reasonable clinical evaluation starts with the pattern of symptoms. Is the primary complaint firmness, duration, libido, ejaculation, orgasm, penile curvature, pain, fatigue, or anxiety? Are morning erections present? Did symptoms begin gradually or suddenly? Is the problem consistent across contexts or partner-specific? Are there new medications, antidepressants, blood pressure drugs, opioids, finasteride, anabolic steroid exposure, alcohol changes, or sleep disruption?
Laboratory testing is individualized. For men with low libido, reduced morning erections, infertility concerns, testicular symptoms, pituitary symptoms, or unexplained fatigue, morning testosterone testing may be appropriate. If low, it should generally be repeated and interpreted with related markers. Men who want future fertility need special caution because exogenous testosterone can suppress sperm production.
Treatment should match the dominant mechanism. Testosterone replacement is a medical therapy for confirmed deficiency, not a general performance enhancer. PDE5 inhibitors are evidence-based first-line therapies for many men with ED, but safety screening is essential, particularly around nitrates, unstable cardiovascular disease, severe hypotension, and complex medication regimens. When ED is persistent, worsening, or associated with chest pain, exertional symptoms, penile deformity, neurologic symptoms, or very low libido, clinician evaluation is more important than trial-and-error treatment.
Conclusion
Testosterone is important for male sexual health, but erectile dysfunction is broader than testosterone alone. The strongest clinical approach is to identify the dominant contributors: androgen deficiency when present, vascular risk, sleep, metabolic health, medication effects, psychological stress, and PDE5 pathway responsiveness. For some men, testosterone evaluation is essential. For many others, erectile symptoms are better explained by vascular and lifestyle factors, with PDE5-based therapy considered after appropriate medical screening.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including EPIQ CHEWS, starting with a free online assessment at questionnaire.getonyxmd.com. You can also review related men's health articles in the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Wang Y, Jiang R. Androgens and erectile dysfunction: from androgen deficiency to treatment. Sexual Medicine Reviews. 2024;12(3):458-468. doi:10.1093/sxmrev/qeae030
- Pencina KM, Travison TG, Cunningham GR, Lincoff AM, Nissen SE, Khera M, et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. The Journal of Clinical Endocrinology & Metabolism. 2024;109(2):569-580. doi:10.1210/clinem/dgad484
- Lee H, Hwang EC, Oh CK, Lee S, Yu HS, Lim JS, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database of Systematic Reviews. 2024;1:CD013071. doi:10.1002/14651858.CD013071.pub2
- Xu Z, Chen X, Zhou H, Ren C, Wang Q, Pan Y, et al. An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate. Frontiers in Endocrinology. 2024;15:1335146. doi:10.3389/fendo.2024.1335146
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.